Cyramza First-Line Lung Cancer Bid Raises Clinical Practice Questions
Lilly Drug Wins Narrow FDA Advisory Committee Backing
Executive Summary
Lilly is positioning the ramucirumab/erlotinib combination as a first-line alternative for EGFR-positive non-small cell lung cancer that preserves AstraZeneca’s Tagrisso for second-line use; advisory committee members vote 6-5 for expanded indication but express skepticism about adoption.